Powder: -20°C for 3 years | In solvent: -80°C for 1 year
YF135, a reversible-covalent KRAS G12C PROTAC, effectively induces the degradation of KRAS G12C and reduces phospho-ERK levels via the E3 ligase VHL-mediated proteasome pathway. Designed by integrating the KRAS G12C inhibitor 48 (compound 6d) as the ligand, YF135 utilizes the MRTX849 linkage VHL ligand scaffold.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | Inquiry | Inquiry | |
50 mg | Inquiry | Inquiry |
Description | YF135, a reversible-covalent KRAS G12C PROTAC, effectively induces the degradation of KRAS G12C and reduces phospho-ERK levels via the E3 ligase VHL-mediated proteasome pathway. Designed by integrating the KRAS G12C inhibitor 48 (compound 6d) as the ligand, YF135 utilizes the MRTX849 linkage VHL ligand scaffold. |
Molecular Weight | 1179.86 |
Formula | C63H75ClN12O7S |
CAS No. | 2913177-53-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
YF135 2913177-53-2 inhibitor inhibit